Article
Medicine, General & Internal
Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Perez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
Swayamjeet Satapathy, Ranjit K. Sahoo, Chandrasekhar Bal
Summary: This study aimed to evaluate the impact of prior taxane chemotherapy on response and survival outcomes in mCRPC patients after [177Lu]Lu-PSMA-RLT. Results showed that taxane-naive patients had significantly better outcomes in terms of biochemical response rate, progression-free survival, and overall survival after [177Lu]Lu-PSMA-RLT. Further trials in the taxane-naive setting are required to confirm these findings.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Medicine, General & Internal
Friederike Voelter, Lena Mittlmeier, Astrid Gosewisch, Julia Brosch-Lenz, Franz Josef Gildehaus, Mathias Johannes Zacherl, Leonie Beyer, Christian G. Stief, Adrien Holzgreve, Johannes Ruebenthaler, Clemens C. Cyran, Guido Boning, Peter Bartenstein, Andrei Todica, Harun Ilhan
Summary: The study found that single index-lesion-based SPECT dosimetry correlates well with the response to PSMA-RLT, suggesting it may be a fast and feasible dosimetry approach for clinical routine.
Article
Radiology, Nuclear Medicine & Medical Imaging
Nahid Yusufi, Alexander Wurzer, Michael Herz, Calogero D'Alessandria, Benedikt Feuerecker, Wolfgang Weber, Hans-Juergen Wester, Stephan Nekolla, Matthias Eiber
Summary: The study evaluated the biodistribution, dosimetry, and therapeutic efficacy of F-19/Lu-177-rhPSMA-7.3 compared to Lu-177-PSMA I&T, showing superior tumor uptake and retention for F-19/Lu-177-rhPSMA-7.3. Preliminary treatment experiments demonstrated a favorable antitumor response for F-19/Lu-177-rhPSMA-7.3 compared to Lu-177-PSMA I&T.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wojciech Cytawa, Robin Hendel, Bartlomiej Tomasik, Franz-Xaver Weinzierl, Thorsten Bley, Jacek Jassem, Andreas Schirbel, Andreas K. Buck, Ralph A. Bundschuh, Philipp E. Hartrampf, Rudolf A. Werner, Constantin Lapa
Summary: The purpose of this study was to investigate the radiographic PSMA PET response after one cycle of [Lu-177]Lu-PSMA I & T RLT in mCRPC patients and to assess its role in predicting overall response and survival. The results showed that early PSMA PET radiographic response was not associated with overall survival, indicating that treatment should not be discontinued prematurely. However, early PSA progression after one cycle of [Lu-177]Lu-PSMA I & T RLT was an indicator of overall progression and poor clinical outcome.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Sachindra Sachindra, Teresa Hellberg, Samantha Exner, Sonal Prasad, Nicola Beindorff, Stephan Rogalla, Richard Kimura, Sanjiv Sam Gambhir, Bertram Wiedenmann, Carsten Groetzinger
Summary: The study evaluated a high-affinity molecular probe targeting PDAC tumors, showing promising tumor accumulation and moderate, rapidly declining kidney uptake for the tracer Lu-177-DOTA-integrin alpha v beta 6 knottin. These results support further preclinical treatment studies to establish therapeutic efficacy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Ioanna Stamouli, Thomas Nanos, Konstantinos Chatzipapas, Panagiotis Papadimitroulas, Lydia-Aggeliki Zoglopitou, Theodoros Kalathas, Paraskevi F. Katsakiori, Anna Makridou, George C. Kagadis
Summary: This study compared the commercial dosimetric software Planet(R) Dose from DOSIsoft and the open-source toolkit GATE. Dose calculations were performed for six patients receiving Lutathera(R) treatment. Planet(R) used SPECT/CT images acquired at different time points, while GATE utilized SPECT images at 24 hours and CT images for attenuation maps. The results showed differences in absorbed dose calculations between the software, with bi-exponential fitting being more similar to GATE.
APPLIED SCIENCES-BASEL
(2023)
Review
Oncology
Konstantin Egon Seitzer, Robert Seifert, Katharina Kessel, Wolfgang Roll, Katrin Schlack, Martin Boegemann, Kambiz Rahbar
Summary: There are various treatment options available for patients with advanced prostate cancer, and Lu-PSMA radioligand therapy is one effective and relatively low side effect option. Researchers are focusing on minimizing adverse events and finding better treatment regimens. The efficacy of Lu-177-PSMA therapy has been confirmed, and future studies will focus on early disease stages and combination therapy.
Article
Radiology, Nuclear Medicine & Medical Imaging
Michael Mix, Tobias Renaud, Felix Kind, Ursula Nemer, Elham Yousetzadeh-Nowsha, Tumelo C. G. Moalosi, Aymen M. Ormrane, Philipp T. Meyer, Juri Ruf
Summary: This study analyzed the monitoring and estimation methods of kidney dose in prostate cancer patients undergoing radioligand therapy. The results showed that pretherapeutic kidney function is not a reliable predictor of subsequent kidney dose, and individual first-cycle dose estimation is more accurate. The integration of dose information from multiple cycles further improves the prediction.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Song Xue, Andrei Gafita, Chao Dong, Yu Zhao, Giles Tetteh, Bjoern H. Menze, Sibylle Ziegler, Wolfgang Weber, Ali Afshar-Oromieh, Axel Rominger, Matthias Eiber, Kuangyu Shi
Summary: This study aimed to prove the concept of pretherapeutic prediction of dosimetry based on imaging and laboratory measurements before prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT). Machine learning methods were explored for dose prediction using organ SUVs and laboratory measurements. The preliminary results confirmed the feasibility of pretherapeutic estimation of treatment dosimetry and its added value to empirical population-based estimation.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Charito Love, Neil B. Desai, Tony Abraham, Kevin P. Banks, Lisa Bodei, Thomas Boike, Richard K. J. Brown, David L. Bushnell, Lorraine E. DeBlanche, Michael M. Dominello, Tony Francis, Erin C. Grady, Robert F. Hobbs, Thomas A. Hope, Jeffrey S. Kempf, Daniel A. Pryma, William Rule, Bital Savir-Baruch, Ila Sethi, Rathan M. Subramaniam, Ying Xiao, Naomi R. Schechter
Summary: This practice parameter provides guidance for selecting appropriate adult candidates with gastroeneropancreatic neuroendocrine tumors (GEP-NETS) for Lutetium-177 (Lu-177) DOTATATE peptide receptor radionuclide therapy (PRRT). Lu-177 DOTATATE is a radiopharmaceutical that can effectively treat inoperable and advanced GEP-NETs. The document ensures safe handling of Lu-177 DOTATATE by authorized users and safe management of affected patients.
CLINICAL NUCLEAR MEDICINE
(2022)
Article
Medicine, General & Internal
Gefei Chen, Zhonglin Lu, Han Jiang, Ali Afshar-Oromieh, Axel Rominger, Kuangyu Shi, Greta S. P. Mok
Summary: This study evaluated two-time-point methods for time-integrated activity (TIA) calculation in kidneys and tumors. The results showed that the TTP methods using 20h-60h and 40h-200h had smaller mean absolute errors compared to other combinations of time points and single-time-point (STP) methods.
FRONTIERS IN MEDICINE
(2023)
Article
Oncology
An-Dong Liu, Jie Zhou, Xiao-Yang Bi, Guo-Qing Hou, Shawn Shun-Cheng Li, Qing Chen, Hui Xu, Xuan Cao
Summary: The XQ-2d-SH2 CM-(Arg)9 conjugate shows potent efficacy in treating PDAC by blocking pY-related signaling pathways, inhibiting proliferation and metastasis of cancer cells, and eliminating the dense stroma of tumors.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Typhanie Ladriere, Julie Faudemer, Elise Levigoureux, Damien Peyronnet, Cedric Desmonts, Jonathan Vigne
Summary: Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 (Lu-177) based radiopharmaceuticals has become a personalized treatment approach in nuclear medicine and oncology. The efficacy of Lu-177 radiopharmaceuticals has been well-reported, but data on patient safety and management are needed. This review focuses on tailored approaches to optimize the risk-benefit trade-off of radioligand therapy using approved Lu-177 based radiopharmaceuticals.
Review
Chemistry, Multidisciplinary
Siju C. C. George, E. James Jebaseelan Samuel
Summary: This review provides an overview of currently available Lu-177-labelled radioligands for treatment and evaluates the challenges and opportunities in assessing patient-specific dosimetry to ensure safety and efficacy. It also discusses the challenges and opportunities of existing dosimetry standards and highlights areas for further research to improve patient treatment outcomes.
FRONTIERS IN CHEMISTRY
(2023)
